Published in final edited form as:

Dev Psychopathol. 2018 February ; 30(1): 143–152. doi:10.1017/S0954579417000529.

Association of Cognitive Function and Liability to Addiction with Childhood Herpesvirus Infections: A Prospective Cohort Study

Michael M. Vanyukov^{a,b,c}, Vishwajit L. Nimgaonkar^{b,c}, Levent Kirisci^{a,b}, Galina P. Kirillova^a, Maureen D. Reynolds^a, Konasale Prasad^b, Ralph E. Tarter^{a,b}, and Robert H. Yolken^d

^aDepartment of Pharmaceutical Sciences, University of Pittsburgh

^bDepartment of Psychiatry, University of Pittsburgh

^cDepartment of Human Genetics, University of Pittsburgh

^dStanley Laboratory of Developmental Neurovirology, Department of Pediatrics (RHY), Johns Hopkins University School of Medicine

Abstract

Liability to substance use disorder (SUD) is to a large degree non-specific to particular drugs, and is related to behavior dysregulation, including reduced cognitive control. Recent data suggest that cognitive mechanisms may be influenced by exposure to neurotropic infections, such as human herpesviruses (HHV). In this study, serological evidence of exposure to HHV (herpes simplex virus type 1, HSV-1; cytomegalovirus, CMV; Epstein-Barr virus, EBV) as well as *Toxoplasma gondii* was determined in childhood (age ~11 years) in 395 sons and 174 daughters of fathers with or without SUD. Its relationships with a cognitive characteristic (IQ) in childhood and with risk for SUD in adulthood were examined using correlation, regression, survival, and path analyses. Exposure to HSV-1, EBV, and *T. gondii* in males and females, and CMV in males, was associated with lower IQ. Independently of that relationship, EBV in females and possibly in males, and CMV and possibly HSV-1 in females were associated with elevated risk for SUD. Therefore, childhood neurotropic infections may influence cognitive development and risk for behavior disorders such as SUD. The results may point to new avenues for alleviating cognitive impairment and SUD risk.

Substance use disorders (SUD; addictions) are outcomes of phenotypic development superimposed on the physiological and behavioral ontogenesis (Tarter & Vanyukov, 1994). Genetic differences play a significant role in individual variation in these developmental processes and liability to addiction, but the contribution of environment to liability variance is also substantial (e.g., Vanyukov et al., 2015). In addition to the obvious candidates such as availability of drugs, concrete factors that may account for the environmental component are of special interest because of their possible malleability.

Corresponding author: Michael Vanyukov, University of Pittsburgh, 3501 Terrace St., 541A Salk Hall, Pittsburgh, PA 15261, Pittsburgh, PA 15213, mmv@pitt.edu.

Financial disclosures

The authors reported no biomedical financial interests or potential conflicts of interest.

Neurotropic infections, particularly human herpesviruses (HHV), may play a role in these mechanisms by influencing the central nervous system (CNS) and thus behavior regulation. Virions can migrate to ganglia (herpes simplex types 1 and 2, HSV-1 and HSV-2; and varicella zoster, VZV), or B-cells (Epstein-Barr virus, EBV), or lymphoid tissue (cytomegalovirus, CMV; HHV-6; HHV-7; HHV-8) where they enter latency, during which the viral genomes may lie dormant throughout the lifetime of the host (Gilden et al., 2007; Steiner, Kennedy & Pachner, 2007). Upon reactivation, however, all of HHV except HHV-8 (Kaposi's sarcoma-associated herpesvirus) can cause severe, albeit infrequent, neurological disease (Gilden et al., 2007). Acute CNS pathology due to HHV is rare, and these infections are thus considered relatively benign for the CNS. Nonetheless, HSV-1 and CMV have been repeatedly associated with cognitive deterioration – even in apparently healthy adults without a history of encephalitis (Prasad et al., 2012; Tarter et al., 2014; Thomas et al., 2013; Dickerson et al., 2014a; Shirts et al., 2008; Ahn et al., 1996; Dickerson et al., 2014b; Aiello et al., 2008). Cognitive decline was also observed in adult HSV-1-exposed individuals with schizophrenia (Prasad et al., 2011) and in older individuals exposed to cytomegalovirus (Nimgaonkar et al., 2016).

The impact of an environmental SUD risk factor may be particularly important if it occurs in childhood, thus contributing to the trajectory of liability phenotype development (Vanyukov & Tarter, 2000). Although the association of childhood EBV infection with IQ-measured intelligence in adolescence did not reach significance after adjustment for potential confounders, this infection was associated with elevated risk for psychotic experiences (Khandaker et al., 2014). Reports also suggest associations of HSV-1 and CMV exposure with cognitive function impairment in children (Tarter et al., 2014), and HSV-1 but not CMV or EBV in adolescents (Jonker et al., 2014). The length – six months vs. six weeks – of antiviral treatment of neonates with symptomatic congenital CMV disease was related to cognitive improvement at 24 months (Kimberlin et al., 2015). In turn, cognitive deficits have long been associated with behavioral sequelae, such as antisociality and SUD (e.g., Aytaclar et al., 1999; Giancola et al., 1996). Substance abuse results in further cognitive deterioration (Gould, 2010). Focusing on SUD thus provides an opportunity of identifying a relationship of high importance. It is essential to examine these associations in children – particularly, from peri-adolescence, characterized by active brain maturation, which is also a period of vulnerability to neurocognitive precursors of SUD (Casey & Jones, 2010) that may have long-term behavioral consequences.

We hypothesize that exposure to highly prevalent neurotropic HHV (HSV-1, EBV, and CMV) is related to cognitive function as measured by IQ in children, and to their risk for drug addiction in adulthood, possibly mediated by IQ. In addition, the study tested the effects of a non-viral agent, *Toxoplasma gondii*, which has been implicated in lower levels of cognitive functioning in adults (Flegr et al., 2003).

These relationships are also hypothesized to vary by sex. Extensive sex differences exist for SUD and its mechanisms (e.g., rev. in Becker & Hu, 2007; Becker et al., 2017; Sanchis-Segura & Becker, 2016), as well as in IQ, including differential item functioning (Maller, 2001). These mechanisms involve neuroanatomical, neurochemical, and psychological differences, many of which are relevant to the variables under study (e.g., rev. in Ngun et al.,

2011). Importantly, differential susceptibility to and recovery from viral infection of the central nervous system in males and females has been demonstrated in both experimental animals (Bama et al., 1996; Geurs et al., 2012) and humans (Muenchhoff & Goulder, 2014), likely related to sex differences in immune response. This calls for not merely controlling for effects of sex, or even taking into account the potential interactions of sex (and, implicitly, related biological factors) with other variables by entering respective interaction terms into equations, but studying these relationships separately in males and females. For instance, in our research, an association of SUD risk with a polymorphism in the *AVPR1A* gene, known to be involved in variation in social and affiliative behaviors in a sexually dimorphic fashion, was detected in males, but not in females (Maher et al., 2011). Analyses separated by sex not only provide greater detail, but regression-based conditioning does not allow estimating sex-specific effects, one of the goals of this study. While the non-significance of an interaction term in a regression framework may result from insufficient power, a Type II error, a stratified analysis may reveal an important effect. Sex is an important biological factor rather than merely a confounder or nuisance variable, and its potential effects are beyond quantitative. Moreover, females are an understudied population in addiction research. These considerations, as well as understanding that “disaggregation of data by sex allows for sex-based comparisons and may inform clinical interventions” (NIH, 2015), have converged into the current NIH “rigor and reproducibility” requirement of thorough consideration of sex in research, including “appropriate analysis and transparent reporting of data by sex” (NIH, 2016), with which this study comports. To our knowledge, there have been no publications covering these relationships, involving highly prevalent neurotropic infections and cognitive and behavioral development, and HHV-cognitive function association studies have been largely conducted in middle-aged and older adults.

Method

Participants

The participants were 160 white and 61 black females, and 425 white and 108 black males, for 569 of whom (395 males and 174 females) blood serum samples were available for immunoassays related to the infectious agents under study. The participants were recruited at age 10–12 (mean $\pm$ SE: 11.4 ± 0.04) and assessed prospectively until age ~30 in the Center for Education and Drug Abuse Research (CEDAR), a longitudinal family/high-risk study of etiology of substance use disorder (SUD; substance abuse or dependence) (Tarter & Vanyukov, 2001). The probands in that study were the participants’ fathers who either had a lifetime DSM-III-R diagnosis of SUD consequent to use of illicit drugs (47.5%) or did not have SUD (52.5%), or had another psychiatric disorder (psychiatric control; 11%). Among the mothers, 23.6% were also affected with SUD. The affected fathers were recruited from treatment programs, social service agencies, newspaper and radio advertisements, public service announcements, and random digit telephone calls. The unaffected probands were recruited using the same sources, except treatment facilities. The family was excluded from study if the father had a history of neurological disorders, schizophrenia, or uncorrectable sensory incapacity, or the participant child had a history of neurological injury requiring hospitalization, IQ < 70, chronic physical disability, uncorrectable sensory incapacity, or psychosis. This study used IQ data and blood serum obtained at the baseline assessment, and

the SUD outcome by the participant's last available assessment. The average age of the participants at their last assessment was 25.2 ± 0.19 years (range 10–31).

This study was reviewed and approved by the Institutional Review Board of the University of Pittsburgh. Participants under age 18 signed assent forms before the research protocols were administered, and written informed consent was obtained from the parents. Upon reaching age 18, participants provided informed consent themselves. In addition, a copy of Certificate of Confidentiality issued by the National Institute on Drug Abuse to CEDAR was given to the participants. Prior to implementing the assessment protocols, breath, saliva and urine samples were collected and analyzed to ensure that alcohol, nicotine and drugs did not impact the cognitive performance tests.

Variables

The main predictor of interest was the infection status pertaining to human herpesviruses herpes simplex type 1 (HSV-1), Epstein-Barr virus (EBV), and cytomegalovirus (CMV), as well as to *T. gondii*, as indicated by the levels of antibodies (see Laboratory Analysis below). Ethnicity (black or white) was determined by self-report. Socioeconomic status (family SES) (Hollingshead, 1975) was measured according to the standard factors: education (7-point score based on years of schooling: 1, less than a 7th-grade education, and 7, graduate training), occupation (9-point score based on the category of occupation based on a comprehensive list of professional titles: 1, corresponding to farm laborer/mental service or unemployment, and 9, higher executives, owners of large businesses and major professionals), sex, and marital status. The family score is computed from the weighted rankings of education (rank multiplied by 3), occupation (rank multiplied by 5), and marital status of the heads of household and their relationship to the labor force. Computed family SES scores range from 8 to 66. To control for parental SUD, which can be a correlate or indicator of factors relevant to the risk for infections, we included both paternal and maternal SUD diagnoses in the models, summarized in the number of affected parents, NAP (0–2), as employed in our prior research (Kirillova et al., 2008). Diagnosis of SUD (alcohol or illicit drug use disorder) in parents and children (if age 19 or older) was determined using an expanded version of the Structured Clinical Interview for DSM-III-R-outpatient version (SCID-OP)(Spitzer, Williams & Gibbon, 1996), and finalized in a consensus conference using the best estimate procedure (Kosten & Rounsaville, 1992). The expanded SCID evaluates current episode (past 6 months) and worst past episode of psychopathology (before the past 6 months). Wechsler Intelligence Scale for Children (WISC-III; full scale IQ) at the baseline visit was used as a measure of cognitive capacity. The WISC-III is measured on an interval scale, standardized to have a mean of 100 and a standard deviation of 15 (Wechsler, 1991).

Laboratory analysis

Blood samples were collected from children at the baseline visit, and serum was separated by centrifugation, aliquoted in 1 ml samples, and stored at -80°C until assay. Antibodies to HSV-1 were assayed using kits (Focus Diagnostics, Cypress, CA) for microplate solid-phase enzyme immunoassays (ELISA) for immunoglobulin G (IgG) antibody detection (Dickerson et al., 2003). These assays utilized purified glycoproteins, and reference samples were

placed on every plate. Antibody level was expressed as the ratio of the sample signal and the mean reference standard on the same microplate. Exposure was defined as a level of antibody greater than the cutoff indicated by the manufacturer. IgG class antibodies to *T. gondii*, cytomegalovirus (CMV), and Epstein-Barr virus (viral capsid antigen) were measured using solid phase immunoassay kits (IBL-America, <http://www.ibl-america.com>) according to protocols provided by the manufacturer. To maximize certainty, data with the manufacturer-suggested indeterminate values for a particular agent (~1–3% of the sample for the various agents) were not used in the analyses of the relationships involving that agent.

Statistical methods

The bivariate relationships were initially evaluated using correlation analysis (contingency coefficients, point-biserial, or product-moment, as appropriate for the types of variables involved) and linear regression (for IQ as the dependent variable). The relationships of predictors with the rate of SUD development were assessed by survival analysis (Cox proportional hazard regression). Correlation and survival analyses were conducted using IBM SPSS for Windows version 24. All multivariate analyses were specific to each infectious agent.

The multivariate relationships evaluating effects of infections on SUD outcome and the potential role of IQ as a mediator of these relationships, taking into account SES, ethnicity, and parental SUD, were then modeled using path analysis. Path models were estimated using IBM SPSS Amos 24 (Arbuckle, 2016). Males and females were analyzed separately, and two-group (males and females) path analysis was conducted to test the models relating childhood infections and cognitive function, and SUD in adulthood, controlling for SES, parental SUD, and ethnicity as potential confounders, and compare the infections' effects between sexes.

Path analysis allows controlling for the relationships between independent variables, such as SES, parental SUD, ethnicity, and the infections in this study, thus taking care of both multicollinearity and, importantly, the unaccounted-for common sources of variance or directional relationships causing correlations among exogenous variables (SES, NAP, and ethnicity – data not shown, available upon request). It is also possible that SES, NAP, and infections are related to attrition and thus the age at the last available assessment, which, in turn, may contribute to the risk for drug exposure and SUD. Evaluation of indirect effects enables testing mediation (McKinnon, 2008). Bayesian structural equation modeling (SEM) implemented in Amos was used to test the models. Bayesian SEM has been shown to be more robust than the maximum likelihood approach in parameter estimation in relatively small samples by using proper or improper prior distributions (Lee and Song, 2004). It employs the Markov chain Monte Carlo (MCMC) algorithm, which draws samples from the posterior distribution of model parameters, an iterative process that is allowed to continue until convergence is established. The latter is evaluated by the convergence statistics (C.S.), measuring how much uncertainty about a parameter can be reduced (or precision gained) by increasing the number of observations to infinity. We used the conservative default criterion of overall C.S. < 1.002 to diagnose convergence. To evaluate the uncertainty about a

parameter estimate, analogous to a confidence interval, Bayesian analysis uses a credible interval, the range of parameter values between percentiles of the marginal posterior probability distribution, e.g., 2.5 and 97.5. This would correspond to a 95% credible interval, interpretable as a 95% certainty of a parameter's true value lying between the lower and upper parameter values of the interval. In addition, this analysis provides an opportunity to estimate the probability of a dichotomous state of a parameter (dichotomous estimand), such as being greater or less than zero, using areas under a marginal posterior distribution to evaluate paths where the credibility interval covers zero (a tail area is then an analog of a p value for testing the null hypothesis). The program also allows estimation of custom parameters, including specific indirect paths and total effects (sums of direct and indirect paths) from exogenous to endogenous variables (e.g., from the infection status to the SUD diagnosis). While focusing on direct paths from infections to IQ and SUD and indirect paths from infections to SUD mediated by IQ, all direct and indirect effects were tested accordingly. Default prior distributions (priors) provided by the software were used. To control for the positive relationship of the age of the last assessment with the risk for SUD, this age was entered as a regressor for the SUD diagnosis in the path models (Fig. 1).

Results

Descriptive statistics

Table 1 presents seropositivity for the participants at the baseline assessment for HSV-1, EBV, CMV, and *T. gondii*. There were no significant sex differences for seropositive status, as well as for SES (mean $\pm$ SE: 41.3 $\pm$ 0.50), and age at the last visit (25.2 $\pm$ 0.19), whereas the differences in age at the first visit were trivial (11.4 $\pm$ 0.04 vs. 11.5 $\pm$ 0.06 in males and females, respectively; $p=.02$, nonsignificant after Bonferroni correction).

Males had on average a 3-point higher IQ than females (107.8 $\pm$ 0.67 vs 104.8 $\pm$ 1.06; $p = .016$). There were no significant sex differences in the age of SUD onset (males: 17.7 $\pm$ 0.21; females: 17.6 $\pm$ 0.36; $p = .7$). However, there were sex differences in SUD prevalence by the last assessment (31.9% in females vs. 44.1% in males, $p=.002$). While both female and male groups were enriched for SUD due to the high-risk design of the study, and the prevalence-based estimates thus should not be considered population estimates, the sex differences in SUD prevalence hold at the same level within the offspring of unaffected fathers (26.4% vs. 38.7%). These differences, as well as other relevant facts and considerations presented above, entail the necessity of analyzing males and females separately, with the goal of obtaining sex-specific estimates.

Bivariate relationships

Table 2 presents associations between the infection status for the agents under study and the outcomes of interest, IQ and SUD diagnosis. As can be seen, serological evidence of HSV-1 and EBV infections is associated with the phenotypic variables, except that the correlations of HSV with SUD in both sexes, and EBV in males, do not reach significance. Importantly, both HSV-1 and EBV infections negatively correlate with IQ. These correlations, including the nonsignificant CMV and *T. gondii* ones, do not, however, take into account the potential confounding effect of family environment such as that indicated by the SES.

Supporting the study's hypotheses, HSV-1 and EBV exposures are associated with lower IQ. In males and females, respectively, HSV-1 exposure is related to an average IQ decrease of 7.3 (95% CI for the difference: 3.16–11.34; $p=.001$) and 6.9 ([0.38, 13.52]; $p=.039$) units. Similarly, EBV is related to a 5.3 ([2.16, 8.39]; $p=.001$) and 10.7 ([5.87, 15.60]; $p=2\times 10^{-5}$) unit difference in IQ in males and females, respectively.

Multivariate analysis

Survival analysis—Results (Table 3) of Cox regression analysis, controlling for SES and stratified by ethnicity, indicate a relationship of childhood EBV infection with the rate of SUD development in females: hazard ratio $HR = 2.0$ [1.13, 3.50]; $p = .016$. This relationship does not reach significance in males: $HR=1.3$ [0.95, 1.80]; $p=.096$. CMV is also associated with the SUD rate in females ($HR= 1.7$ [1.01, 3.04], $p < .05$), but not in males. There appears to be a trend for the HSV-1 relationship with the rate of SUD development in females ($HR=1.7$ [0.91, 2.95]; $p = .097$) and, somewhat weaker, in males ($HR=1.3$ [0.91, 1.99]; $p = .141$). It may be noted that even where these relationships are not significant, they are numerically comparable and trend in the same direction, indicating a possibility of indirect/mediated effects and/or insufficient power. This is in contrast to the effects of *T. gondii*, where no such trend is apparent. The overlapping confidence intervals of respective hazard ratios do not support sex dimorphism in these effects.

Path analysis—To evaluate the relationship between exposure to the infections under study and the phenotypic characteristics (IQ and SUD liability), while controlling for possible confounders (ethnicity, SES, and parental SUD diagnosis), we tested the path model presented in Fig. 1, estimating direct and indirect effects of exposure to an infection. The unstandardized path coefficients (b) are presented in Table 4. The results for IQ in males suggest a drop of ~3 points due to HSV-1, ~2 points for EBV, and ~3 points for *T. gondii*. There is only a small effect detected for CMV. The estimates for females are somewhat lower for HSV and EBV (both at ~1 unit), show no IQ decrease for CMV (if not, paradoxically, an increase), and suggestive of a decrease by 1.6 for *T. gondii*.

For SUD, the results are suggestive of EBV effect in both sexes, and the effect of HSV-1 in females and, somewhat weaker, in males, and CMV in females, but no effect for CMV in males, and no *T. gondii* effect in either sex. Nevertheless, the overlapping credible intervals for the respective parameters in males and females do not indicate sex dimorphism in the relationships studied. These results largely parallel those observed in survival analysis. No infectious agent-SUD diagnosis relationship is mediated by IQ (data not shown), as the indirect paths involving IQ are not significant because the direct effect of IQ on SUD risk is close to 0 (corresponding to an odds ratio close to 1.0). None of the probabilities of a higher than 0 indirect effect from the infectious agents to SUD was greater than 0.5 either.

Discussion

The results of this longitudinal study are suggestive of relationships between seropositivity for common neurotropic infections HSV-1, EBV, and *T. gondii* in both sexes, and possibly CMV in males but not females, with lowered intelligence. Independent of these relationships, childhood EBV and HSV-1 infections in both sexes, and CMV in females, are

associated with elevated risk for SUD in adulthood. This is the first study that relates childhood HHV and *T. gondii* infections, cognitive function, and SUD risk, and establishes the HHV-SUD risk connection. Most publications regarding cognitive impairment are in middle-aged or older individuals, whereas this study spans ages from pre-adolescence to adulthood. Few studies have addressed the association between HHV exposure and cognitive dysfunction. Few studies that we are aware of examined HHV seropositivity in relation to cognitive function in children (Tarter et al., 2014; Jonker et al., 2014; Kimberlin et al., 2015).

Substance abuse is an enormous health and societal burden. It is often lethal and contributes to morbidity and mortality on virtually every major health condition. A tremendous opportunity cost is incurred, due to arrested social development, criminality, educational underachievement, and under- and unemployment. The cost to society is estimated over \$600 billion (Volkow, 2012). The persistent severity of the problem calls for novel research that could be readily translated into prevention and treatment. The effect of any malleable factor on liability to addiction may be of great significance for intervention even if it is statistically small under natural conditions. It would be especially important if that factor contributed to variation in non-drug-specific, general liability to addiction (GLA), substantially shared in common between risks for drug-specific disorders (Vanyukov et al., 2012).

It is possible that one of such factors is HHV and other neurotropic infections. Cycles of HHV latency and recurrence in relatively small brain regions may lead to cumulative impairment in cognitive function, even though each cycle individually may produce no overt symptoms. It is also possible that initial exposure to neurotropic infections in childhood causes subclinical brain damage that does not recur, but affects neurodevelopment and compromises cognitive function over time. The relationship between cognitive function and risk for behavior deviations including antisociality and SUD is well established (Aytaclar et al., 1999; Kirisci et al., 2004; Giancola et al., 1996). Cognitive impairment has been also observed in adult nonalcoholic offspring of alcoholics, suggesting its role in SUD risk (Gierski et al., 2013). Addiction is a recognized complex psychiatric disorder, but a necessary prodromal condition for its development, drug use, is often voluntary and deliberate, thus requiring cognitive involvement. Inasmuch as HHV infection may contribute to cognitive function, it may be one of the potential developmental mechanisms of SUD liability variation.

Our results are consistent with several studies that showed significant cognitive dysfunction in persons who had elevated serum HSV-1 antibody levels in the absence of signs of encephalitis (Dickerson et al., 2003; Strandberg et al., 2003; Dickerson et al., 2004; Shirts et al., 2008; Dickerson et al., 2008; Schretlen et al., 2010; Prasad et al., 2011; Yolken et al., 2011; Dickerson et al., 2012; Prasad et al., 2012; Watson et al., 2013; Tarter et al., 2014). The HSV-1-related cognitive dysfunction is typically more focal and less severe than the widespread deficits in HSV-1 encephalitis. Brain imaging studies indicate damage in regions that mediate memory and cognition (Prasad et al., 2011; Prasad et al., 2012). Supporting the role of non-encephalitic HSV-1 infection in cognitive function, in a randomized controlled trial, HSV-1-exposed schizophrenia (SZ) patients who received adjunctive valacyclovir, an

anti-HHV drug, showed significant improvement in working, verbal and visual memory compared with the adjunctive placebo group (Prasad et al., 2013). A plausible association between HSV-1 and cognitive dysfunction is also supported by *in vitro* studies indicating that persistent HSV-1 infection can alter the functioning induced pluripotent stem cells (iPSC)-derived neurons (D'Aiuto et al., 2015). HSV-1 exposure is associated with reduced prefrontal cortical gray matter volume among SZ patients (Prasad et al., 2007; Prasad et al., 2011). HSV-1 DNA has been detected in up to 35% of non-encephalitic post-mortem brain tissues (Baringer & Pisani, 1994; Karatas et al., 2008), suggesting viral spread to the brain during persistent infection.

While the observed associations have small to medium effect sizes, the high prevalence of HHV infections may result in a large population attributable risk. Exposure to HSV-1 is noted among approximately 40% of children/teens and over 70% among older adults in the USA (Kruszon-Moran et al., 2012). Seropositivity for EBV increases from ~50% at age 6–8 to over 80% by age 18–19 (Cohen, 2000; Dowd et al., 2013). The cost of cognitive deterioration, particularly if it starts in childhood, is high as it may translate into unrealized potential in academic and consequent professional achievement and quality of life. While cognitive impairment related to HHV infection is *per se* a potential problem, its possible contribution to behavioral disorder risks, including liability to SUD, considerably raises its significance.

The relationship of IQ with SUD is weak to nonexistent, which precludes mediation of the infections' effects on SUD risk by IQ. Nevertheless, there are direct effects of infections on SUD risk, somewhat more prominent in females. Although the overlapping confidence and credible intervals in the survival and path analyses, respectively, do not indicate sex dimorphism in the studied relationships, the hazard ratio for SUD associated with CMV in females is significant and double that in males, in whom it is not significant despite a larger sample. A similar finding is observed for EBV. Notably, the risk for impaired neurodevelopment due to CMV infection is twice as high in females as in males (Picone et al., 2005). Hence, mechanisms other than those indexed by IQ, by which the infections may influence behavior, as well as their sex dimorphism, need to be examined. Such mechanisms may pertain to the executive aspect of cognitive function as well as to behavior regulation. HSV-1 seropositivity was found to be associated with lower reading and spatial reasoning test scores in children, while in a separate sample of middle aged adults HSV-1 and CMV seropositivity were associated with impaired coding speed (Tarter et al., 2014). In older adults, HSV-1 seropositivity was associated with immediate memory impairment. The differences in group profiles raise questions about temporal changes after childhood HHV exposure. We are currently exploring these potential connections.

Importantly, HSV-1 infection is not generally targeted for prevention, and we are aware of no vaccines under development for it. EBV causes substantial morbidity, including infectious mononucleosis, lymphomas, and carcinomas, but vaccine development for this virus has yet to come to fruition as well (Cohen, 2015). In the translation of research findings, it is also important to consider sex differences observed in the immune response to viral infections, including herpesviruses, and in the efficacy of antiviral drugs and vaccines (Klein, 2012).

Several caveats should be noted. It is possible that attrition, unavoidable in a longitudinal study, is greater among those who have developed SUD, and occurs earlier among those whose SUD risk is greater. Considering that attrited individuals in this project have had a lower IQ (Tarter et al., 2006), this may result in the underestimation of the relationships tested. However, the age at last available visit positively correlated with SUD diagnosis (data not shown), likely corresponding to increasing opportunities for drug exposure and consumption with age within the study's scope, perhaps offsetting potential effects of SUD on attrition.

The direct relationship of viral exposure with SUD development is, as expected, relatively weak: the odds ratios, into which the respective path coefficients (b) can be readily converted as $\exp[b]$, reach 1.16 ($b = 0.15$) at maximum (for EBV in females). However, the associations observed in our study are similar to or greater than the effects of other biological variables (e.g., DNA variants) on behavior and related variables that are considered compelling enough to be intensively studied (e.g., Saccone et al., 2009; Hibar et al., 2015). Indeed, there is a considerable functional distance between the behavioral phenotype and the biological mechanisms involved. In a multistep mechanistic relationship, the statistical association between the initial cause (e.g., HSV-1 infection) and the distal outcome (a behavioral trait such as SUD liability) weakens with each consecutive link in the long causal chain – possibly, to nonsignificance – even if the relationship between the adjacent links is strong. The weakness of association may thus belie its importance. The effect of potential practical implementation of findings is expected to be much greater than the “naturally” observed associations.

The results of path analysis, while promising, are not fully satisfactory, because the model does not provide a good fit by the available Bayesian fit criterion, posterior predictive p (ppost or ppp). That value should be around 0.5 for a well-fitting model, but it is zero in this case, indicating lack of fit. The causes for that are unclear, but the literature on the topic suggests that “ppost is simply a way to summarize the results numerically, and has little to do with the probability of rejecting a model in the already known to be false situation where the model is correct” (Levy, 2011). Although it is not entirely certain to what degree the parameter estimates are trustworthy, their congruency with the EBV- and CMV-related Cox regression results in females supports their validity. Bayesian analysis, while fitting both male and female data simultaneously, does not allow a formal comparison of models with restricted (e.g., equal between the groups) and free parameters. Nevertheless, the overlapping confidence and credible intervals in the survival and path analyses, respectively, do not indicate sex dimorphism in the studied relationships. That, however, may result from insufficient power.

It should also be noted that regardless of the associations' validity, causality cannot be firmly established based on these data. It is a common problem that the relationship between exposure and the outcome cannot be readily interpreted in causal terms, particularly in the observational in contrast to experimental studies, and especially when the outcome varies due to multiple causes. For instance, it is possible that the exposure to infections, IQ, and the other variables under study, particularly those measured at the same time, have a common source of variation determining their relationships. In part, this possibility is addressed by

including relevant variables in the analysis and modeling the uncertain relationships between them as correlations rather than regression paths. Modeling the relationships of the predictors with IQ and SUD as directional also does not necessarily denote causality, but rather reflects the predictors' status as fixed variables (no measurement error), whereas IQ and SUD are random variables. Nevertheless, it remains possible that the relationships between the infections and the phenotypic variables are due to an unobserved confounder that is related to both exposure and the outcome. An infection cannot be randomly assigned to humans, to evaluate the average causal effect as is done in treatment response studies or to apply as an instrumental variable (Greenland, 2000) that could turn exposure into a random variable, and solve the problem addressed by Koch postulates and their contemporary developments. Counterfactual reasoning, which derives causality from the positive outcome when a virus is eliminated (e.g., Prasad et al., 2013; Kimberlin et al., 2015), is also often impractical due to the absence of vaccines and effective antivirals (Moore & Chang, 2014). To rule out the third-variable possibility, it is necessary to elucidate a pathophysiological process by which a neurotropic infection can result in cognitive deterioration and/or elevation of SUD risk. Studies in that direction, however, can be undertaken only upon detecting the associations to be elucidated.

Conclusions

The results suggest associations of childhood neurotropic infections (HSV-1, EBV, and *T. gondii* in boys and girls, and CMV in boys) with reduced cognitive capacity. Exposure to EBV in girls and possibly boys, and CMV and possibly HSV-1 in boys, was also associated with greater risk for subsequent development of SUD. The study results may point to new avenues for alleviating cognitive decline and SUD risk through prevention or treatment.

Acknowledgments

This study was supported by the National Institute on Drug Abuse grant P50DA005605, the Stanley Medical Research Institute grant 07R-1712, and the National Institute on Mental Health grant MH63480. The authors are indebted to the staff of the Center for Education and Drug Abuse Research, particularly laboratory assistants Kathleen A. Hartle and Senthil Thillainathan, for their effort and dedication.

References

- Ahn K, Meyer TH, Uebel S, Sempé P, Djaballah H, Yang Y, Peterson PA, Früh K, Tampé R. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. *The EMBO Journal*. 1996; 15:3247–3255. [PubMed: 8670825]
- Aiello AE, Haan MN, Pierce CM, Simanek AM, Liang J. Persistent infection, inflammation, and functional impairment in older Latinos. *The Journals of Gerontology Series A, Biological sciences and medical sciences*. 2008; 63:610–618.
- Arbuckle, JL. IBM® SPSS® Amos™ 24 User's Guide. Chicago: IBM SPSS; 2016.
- Aytaclar S, Tarter RE, Kirisci L, Lu S. Association between hyperactivity and executive cognitive functioning in childhood and substance use in early adolescence. *Journal of the American Academy of Child and Adolescent Psychiatry*. 1999; 38:172–178. [PubMed: 9951216]
- Barna M, Komatsu T, Bi Z, Reiss CS. Sex differences in susceptibility to viral infection of the central nervous system. *Journal of Neuroimmunology*. 1996; 67:31–39. [PubMed: 8707928]
- Baringer JR, Pisani P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. *Annals of Neurology*. 1994; 36:823–829. [PubMed: 7998767]

- Becker JB, Hu M. Sex differences in drug abuse. *Frontiers in Neuroendocrinology*. 2008; 29:36–47. [PubMed: 17904621]
- Becker JB, McClellan ML, Reed BG. Sex differences, gender and addiction. *Journal of Neuroscience Research*. 95:136–147. DOI: 10.1002/jnr.23963
- Casey BJ, Jones RM. Neurobiology of the adolescent brain and behavior: implications for substance use disorders. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2010; 49:1189–1201. DOI: 10.1016/j.jaac.2010.08.017 [PubMed: 21093769]
- Cohen JI. Epstein-Barr virus infection. *New England Journal of Medicine*. 2000; 343:481–492. [PubMed: 10944566]
- Cohen JI. Epstein-Barr virus vaccines. *Clinical & Translational Immunology*. 2015; 4:e32.doi: 10.1038/cti.2014.27 [PubMed: 25671130]
- D'Aiuto L, Prasad KM, Upton CH, Viggiano L, Milosevic J, Raimondi G, McClain L, Chowdari K, Tischfield J, Sheldon M, Moore JC, Yolken RH, Kinchington PR, Nimgaonkar VL. Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance. *Schizophrenia Bulletin*. 2015; 41:123–132. DOI: 10.1093/schbul/sbu032 [PubMed: 24622295]
- Dickerson F, Schroeder J, Stallings C, Origoni A, Katsafanas E, Schwienfurth LA, Savage CL, Khushalani S, Yolken R. A longitudinal study of cognitive functioning in schizophrenia: Clinical and biological predictors. *Schizophrenia Research*. 2014a; 156:248–253. DOI: 10.1016/j.schres.2014.04.019 [PubMed: 24827555]
- Dickerson F, Stallings C, Origoni A, Katsafanas E, Schweinfurth LA, Savage CL, Yolken R. Association between cytomegalovirus antibody levels and cognitive functioning in non-elderly adults. *PLoS One*. 2014b; 9:e95510.doi: 10.1371/journal.pone.0095510 [PubMed: 24846058]
- Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. *Schizophrenia Research*. 2012; 134:83–88. DOI: 10.1016/j.schres.2011.10.003 [PubMed: 22048011]
- Dickerson F, Stallings C, Sullens A, Origoni A, Leister F, Krivogorsky B, Yolken R. Association between cognitive functioning, exposure to Herpes Simplex Virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. *Brain, Behavior, and Immunity*. 2008; 22:1103–1107. DOI: 10.1016/j.bbi.2008.04.156
- Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Cole S, Krivogorsky B, Yolken RH. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. *Biological Psychiatry*. 2004; 55:588–593. DOI: 10.1016/j.biopsych.2003.10.008 [PubMed: 15013827]
- Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. *Archives of General Psychiatry*. 2003; 60:466–472. DOI: 10.1001/archpsyc.60.5.466 [PubMed: 12742867]
- Dowd JB, Palermo T, Brite J, McDade TW, Aiello A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6–19, 2003–2010. *PLoS One*. 2013; 8:e64921.doi: 10.1371/journal.pone.0064921 [PubMed: 23717674]
- Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence among relatives. *Annals of Human Genetics*. 1965; 29:51–76.
- Flegr J, Preiss M, Klose J, Havlicek J, Vitakova M, Kodym P. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite *Toxoplasma gondii* Dopamine, a missing link between schizophrenia and toxoplasmosis? *Biological Psychology*. 2003; 63:253–268. [PubMed: 12853170]
- Geurs TL, Hill EB, Lippold DM, French AR. Sex differences in murine susceptibility to systemic viral infections. *Journal of Autoimmunology*. 2012; 38:245–253. DOI: 10.1016/j.jaut.2011.12.003
- Giancola PR, Martin CS, Tarter RE, Pelham WE, Moss HB. Executive cognitive functioning and aggressive behavior in preadolescent boys at high risk for substance abuse/dependence. *Journal of Studies on Alcohol*. 1996; 57:352–359. [PubMed: 8776676]

- Gierski F, Hubsch B, Stefaniak N, Benzerouk F, Cuervo-Lombard C, Bera-Potelle C, Cohen R, Kahn JP, Limosin F. Executive functions in adult offspring of alcohol-dependent probands: toward a cognitive endophenotype? *Alcoholism, Clinical and Experimental Research*. 2013; 37(Suppl 1):E356–363. DOI: 10.1111/j.1530-0277.2012.01903.x
- Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. *Nature Clinical Practice Neurology*. 2007; 3:82–94. DOI: 10.1038/ncpneuro0401
- Gould TJ. Addiction and cognition. *Addiction Science & Clinical Practice*. 2010; 5:4–14. [PubMed: 22002448]
- Greenland S. An introduction to instrumental variables for epidemiologists. *International Journal of Epidemiology*. 2000; 29:722–729. [PubMed: 10922351]
- Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivieres S, Jahanshad N, Toro R, Wittfeld K, Abramovic L, Andersson M, Aribisala BS, Armstrong NJ, Bernard M, Bohlken MM, Boks MP, Bralten J, Brown AA, Chakravarty MM, Chen Q, Ching CR, Cuellar-Partida G, den Braber A, Giddaluru S, Goldman AL, Grimm O, Guadalupe T, Hass J, Woldehawariat G, Holmes AJ, Hoogman M, Janowitz D, Jia T, Kim S, Klein M, Kraemer B, Lee PH, Olde Loohuis LM, Luciano M, Macare C, Mather KA, Mattheisen M, Milanese Y, Nho K, Papmeyer M, Ramasamy A, Risacher SL, Roiz-Santiañez R, Rose EJ, Salami A, Sämann PG, Schmaal L, Schork AJ, Shin J, Strike LT, Teumer A, van Donkelaar MM, van Eijk KR, Walters RK, Westlye LT, Whelan CD, Winkler AM, Zwiers MP, Alhusaini S, Athanasiu L, Ehrlich S, Hakobjan MM, Hartberg CB, Haukvik UK, Heister AJ, Hoehn D, Kasperaviciute D, Liewald DC, Lopez LM, Makkinje RR, Matarin M, Naber MA, McKay DR, Needham M, Nugent AC, Pütz B, Royle NA, Shen L, Sprooten E, Trabzuni D, van der Marel SS, van Hulzen KJ, Walton E, Wolf C, Almasy L, Ames D, Arepalli S, Assareh AA, Bastin ME, Brodaty H, Bulayeva KB, Carless MA, Cichon S, Corvin A, Curran JE, Czisch M, de Zubicaray GI, Dillman A, Duggirala R, Dyer TD, Erk S, Fedko IO, Ferrucci L, Foroud TM, Fox PT, Fukunaga M, Gibbs JR, Göring HH, Green RC, Guelfi S, Hansell NK, Hartman CA, Hegenscheid K, Heinz A, Hernandez DG, Heslenfeld DJ, Hoekstra PJ, Holsboer F, Homuth G, Hottenga JJ, Ikeda M, Jack CR, Jenkinson M, Johnson R, Kanai R, Keil M, Kent JW, Kochunov P, Kwok JB, Lawrie SM, Liu X, Longo DL, McMahon KL, Meisenzahl E, Melle I, Mohnke S, Montgomery GW, Mostert JC, Mühleisen TW, Nalls MA, Nichols TE, Nilsson LG, Nöthen MM, Ohi K, Olvera RL, Perez-Iglesias R, Pike GB, Potkin SG, Reinvang I, Reppermund S, Rietschel M, Romanczuk-Seiferth N, Rosen GD, Rujescu D, Schnell K, Schofield PR, Smith C, Steen VM, Sussmann JE, Thalamuthu A, Toga AW, Traynor BJ, Troncoso J, Turner JA, Valdés Hernández MC, van't Ent D, van der Brug M, van der Wee NJ, van Tol MJ, Veltman DJ, Wassink TH, Westman E, Zielke RH, Zonderman AB, Ashbrook DG, Hager R, Lu L, McMahon FJ, Morris DW, Williams RW, Brunner HG, Buckner RL, Buitelaar JK, Cahn W, Calhoun VD, Cavalleri GL, Crespo-Facorro B, Dale AM, Davies GE, Delanty N, Depondt C, Djurovic S, Drevets WC, Espeseth T, Gollub RL, Ho BC, Hoffmann W, Hosten N, Kahn RS, Le Hellard S, Meyer-Lindenberg A, Müller-Myhsok B, Nauck M, Nyberg L, Pandolfo M, Penninx BW, Roffman JL, Sisodiya SM, Smoller JW, van Bokhoven H, van Haren NE, Völzke H, Walter H, Weiner MW, Wen W, White T, Agartz I, Andreassen OA, Blangero J, Boomsma DI, Brouwer RM, Cannon DM, Cookson MR, de Geus EJ, Deary IJ, Donohoe G, Fernández G, Fisher SE, Francks C, Glahn DC, Grabe HJ, Gruber O, Hardy J, Hashimoto R, Hulshoff Pol HE, Jönsson EG, Kloszewska I, Lovestone S, Mattay VS, Mecocci P, McDonald C, McIntosh AM, Ophoff RA, Paus T, Pausova Z, Ryten M, Sachdev PS, Saykin AJ, Simmons A, Singleton A, Soininen H, Wardlaw JM, Weale ME, Weinberger DR, Adams HH, Launer LJ, Seiler S, Schmidt R, Chauhan G, Satizabal CL, Becker JT, Yanek L, van der Lee SJ, Ebling M, Fischl B, Longstreth WT, Greve D, Schmidt H, Nyquist P, Vinke LN, van Duijn CM, Xue L, Mazoyer B, Bis JC, Gudnason V, Seshadri S, Ikram MA, Martin NG, Wright MJ, Schumann G, Franke B, Thompson PM, Medland SE. Alzheimer's Disease Neuroimaging Initiative; CHARGE Consortium; EPIGEN; IMAGEN; SYS. Common genetic variants influence human subcortical brain structures. *Nature*. 2015; 520:224–229. DOI: 10.1038/nature14101 [PubMed: 25607358]
- Hollingshead, AB. Four Factor Index of Social Status. Yale University; 1975.
- Karatas H, Gurer G, Pinar A, Soylemezoglu F, Tezel GG, Hascelik G, Akalan N, Tuncer S, Ciger A, Saygi S. Investigation of HSV-1, HSV-2, CMV, HHV-6 and HHV-8 DNA by real-time PCR in surgical resection materials of epilepsy patients with mesial temporal lobe sclerosis. *Journal of the Neurological Sciences*. 2008; 264:151–156. DOI: 10.1016/j.jns.2007.08.010 [PubMed: 17804017]

- Khandaker GM, Stochl J, Zammit S, Lewis G, Jones PB. Childhood Epstein-Barr Virus infection and subsequent risk of psychotic experiences in adolescence: a population-based prospective serological study. *Schizophrenia Research*. 2014; 158:19–24. DOI: 10.1016/j.schres.2014.05.019 [PubMed: 25048425]
- Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, DeBiasi RL, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ. for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. *New England Journal of Medicine*. 2015; 372:933–943. DOI: 10.1056/NEJMoa1404599 [PubMed: 25738669]
- Kirilova GP, Vanyukov MM, Kirisci L, Reynolds M. Physical maturation, peer environment, and the ontogenesis of substance use disorders. *Psychiatry Research*. 2008; 158:43–53. DOI: 10.1016/j.psychres.2007.02.017 [PubMed: 18178256]
- Kirisci L, Tarter RE, Vanyukov M, Reynolds M, Habeych M. Relation between cognitive distortions and neurobehavior disinhibition on the development of substance use during adolescence and substance use disorder by young adulthood: a prospective study. *Drug and Alcohol Dependence*. 2004; 76:125–133. DOI: 10.1016/j.drugalcdep.2004.04.015 [PubMed: 15488336]
- Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatment for viral diseases. *BioEssays*. 2012; 34:1050–1059. DOI: 10.1002/bies.201200099 [PubMed: 23012250]
- Kosten TA, Rounsaville BJ. Sensitivity of psychiatric diagnosis based on the best estimate procedure. *American Journal of Psychiatry*. 1992; 149:1225–1227. [PubMed: 1503136]
- Kruszon-Moran D, Porter KS, McQuillan G, Billieux VG, Kim-Farley R, Hirsch R. Infectious disease prevalence in Los Angeles county--a comparison to national estimates, 1999–2004 birth rates for U.S. teenagers reach historic lows for all age and ethnic groups. *NCHS data brief*. 2012; (90):1–8.
- Lee SY, Song XY. Evaluation of the Bayesian and maximum likelihood approaches in analyzing structural equation models with small sample sizes. *Multivariate Behavioral Research*. 2004; 39:653–686. DOI: 10.1207/s15327906mbr3904_4 [PubMed: 26745462]
- Levy R. Bayesian data-model fit assessment for structural equation modeling. *Structural Equation Modeling: A Multidisciplinary Journal*. 2011; 18(4):663–85. DOI: 10.1080/10705511.2011.607723
- Maher BS, Vladimirov VI, Latendresse SJ, Thiselton DL, McNamee R, Kang M, Bigdeli TB, Chen X, Riley BP, Hettema JM, Chilcoat H, Heidbreder C, Muglia P, Murrelle EL, Dick DM, Aliev F, Agrawal A, Edenberg HJ, Kramer J, Nurnberger J, Tischfield JA, Devlin B, Ferrell RE, Kirillova GP, Tarter RE, Kendler KS, Vanyukov MM. The *AVPR1A* gene and substance use disorders: association, replication, and functional evidence. *Biological Psychiatry*. 2011; 70:519–527. DOI: 10.1016/j.biopsych.2011.02.023 [PubMed: 21514569]
- Maller SJ. Differential item functioning in the WISC-III: Item parameters for boys and girls in the National Standardization Sample. *Educational and Psychological Measurement*. 2001; 61:793–817.
- MacKinnon, DP. Introduction to statistical mediation analysis. New York, NY: Lawrence Erlbaum Associates; 2008.
- Moore PS, Chang Y. The conundrum of causality in tumor virology: the cases of KSHV and MCV. *Seminars in Cancer Biology*. 2014; 26:4–12. DOI: 10.1016/j.semcancer.2013.11.001 [PubMed: 24304907]
- Muenchhoff M, Goulder PJR. Sex differences in pediatric infectious diseases. *The Journal of Infectious Diseases*. 2014; 209(suppl 3):S120–S126. DOI: 10.1093/infdis/jiu232 [PubMed: 24966192]
- NIH. Consideration of Sex as a Biological Variable in NIH-funded Research. 2015. Accessible at <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-102.html>

- NIH. Rigor and Reproducibility. Department of Health and Human Services (DHS), National Institutes of Health, Office of Extramural Research; 2016. Accessible at <http://grants.nih.gov/reproducibility/index.htm#guidance>
- Ngun TC, Ghahramani N, Sanchez FJ, Bocklandt S, Vilain E. The genetics of sex differences in brain and behavior. *Frontiers in Neuroendocrinology*. 2011; 32:227–246. DOI: 10.1016/j.yfrne.2010.10.001 [PubMed: 20951723]
- Nimgaonkar VL, Yolken RH, Wang T, Chung-Chou HC, McClain L, McDade E, Snitz BE, Ganguli M. Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort. *Alzheimer Disease and Associated Disorders*. 2016; 30:216–222. DOI: 10.1097/WAD.0000000000000133 [PubMed: 26710257]
- Picone O, Costa JM, Dejean A, Ville Y. Is fetal gender a risk factor for severe congenital cytomegalovirus infection? *Prenatal Diagnosis*. 2005; 25:34–38. DOI: 10.1002/pd.944 [PubMed: 15662688]
- Prasad KM, Eack SM, Goradia D, Pancholi KM, Keshavan MS, Yolken RH, Nimgaonkar VL. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. *American Journal of Psychiatry*. 2011; 168:822–830. DOI: 10.1176/appi.ajp.2011.10101423 [PubMed: 21632649]
- Prasad KM, Eack SM, Keshavan MS, Yolken RH, Iyengar S, Nimgaonkar VL. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. *Schizophrenia Bulletin*. 2013; 39:857–66. DOI: 10.1093/schbul/sbs040 [PubMed: 22446565]
- Prasad KM, Shirts BH, Yolken RH, Keshavan MS, Nimgaonkar VL. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. *Molecular Psychiatry*. 2007; 12:105–113. 1. DOI: 10.1038/sj.mp.4001915 [PubMed: 17033628]
- Prasad KM, Watson AM, Dickerson FB, Yolken RH, Nimgaonkar VL. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. *Schizophrenia Bulletin*. 2012; 38:1137–1148. DOI: 10.1093/schbul/sbs046 [PubMed: 22490995]
- Saccone NL, Saccone SF, Hinrichs AL, Stitzel JA, Duan W, Pergadia ML, Agrawal A, Breslau N, Grucza RA, Hatsukami D, Johnson EO, Madden PA, Swan GE, Wang JC, Goate AM, Rice JP, Bierut LJ. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. *American Journal of Medical Genetics Part B, Neuropsychiatric Genetics*. 2009; 150B:453–466. DOI: 10.1002/ajmg.b.30828
- Sanchis-Segura C, Becker JB. Why we should consider sex (and study sex differences) in addiction research. *Addiction Biology*. 2016; 21:995–1006. DOI: 10.1111/adb.12382 [PubMed: 27029841]
- Schretlen DJ, Vannorsdall TD, Winicki JM, Mushtaq Y, Hikida T, Sawa A, Yolken RH, Dickerson FB, Cascella NG. Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. *Schizophrenia Research*. 2010; 118:224–231. DOI: 10.1016/j.schres.2010.01.008 [PubMed: 20153952]
- Shirts BH, Prasad KM, Pogue-Geile MF, Dickerson F, Yolken RH, Nimgaonkar VL. Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. *Schizophrenia Research*. 2008; 106:268–274. DOI: 10.1016/j.schres.2008.07.017 [PubMed: 18801645]
- Spitzer, R., Williams, J., Gibbon, M. Structured Clinical Interview for DSM-IV, Outpatient Version (SCID-OP). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
- Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. *Lancet Neurology*. 2007; 6:1015–1028. DOI: 10.1016/S1474-4422(07)70267-3 [PubMed: 17945155]
- Strandberg TE, Pitkala KH, Linnavuori KH, Tilvis RS. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. *Stroke*. 2003; 34:2126–2131. DOI: 10.1161/01.STR.0000086754.32238.DA [PubMed: 12920256]
- Tarter KD, Simanek AM, Dowd JB, Aiello AE. Persistent viral pathogens and cognitive impairment across the life course in the third national health and nutrition examination survey. *The Journal of Infectious Diseases*. 2014; 209:837–844. DOI: 10.1093/infdis/jit616 [PubMed: 24253286]

- Tarter RE, Vanyukov M. Alcoholism: a developmental disorder. *Journal of Consulting and Clinical Psychology*. 1994; 62:1096–1107. [PubMed: 7860808]
- Tarter RE, Vanyukov MM. Introduction: Theoretical and operational framework for research into the etiology of substance use disorders. *Journal of Child & Adolescent Substance Abuse*. 2001; 10:1–12.
- Tarter RE, Vanyukov M, Kirisci L, Reynolds M, Clark D. Predictors of marijuana use in adolescents before and after licit drug use: Examination of the gateway hypothesis. *American Journal of Psychiatry*. 2006; 163:2134–2140. DOI: 10.1176/ajp.2006.163.12.2134 [PubMed: 17151165]
- Thomas P, Bhatia T, Gauba D, Wood J, Long C, Prasad K, Dickerson FB, Gur RE, Gur RC, Yolken RH, Nimgaonkar VL, Deshpande SN. Exposure to herpes simplex virus, type 1 and reduced cognitive function. *Journal of Psychiatric Research*. 2013; 47:1680–1685. DOI: 10.1016/j.jpsychires.2013.07.010 [PubMed: 23920011]
- Vanyukov M, Kim K, Irons D, Kirisci L, Neale M, Ridenour T, Hicks B, Tarter R, Reynolds M, Kirillova G, McGue M, Iacono W. Genetic relationship between the addiction diagnosis in adults and their childhood measure of addiction liability. *Behavior Genetics*. 2015; 45:1–11. DOI: 10.1007/s10519-014-9684-4 [PubMed: 25502189]
- Vanyukov MM, Tarter RE. Genetic studies of substance abuse. *Drug and Alcohol Dependence*. 2000; 59:101–123. [PubMed: 10891624]
- Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA. Common liability to addiction and “gateway hypothesis”: theoretical, empirical and evolutionary perspective. *Drug and Alcohol Dependence*. 2012; 123(Suppl 1):S3–17. DOI: 10.1016/j.drugalcdep.2011.12.018 [PubMed: 22261179]
- Volkow, ND. Testimony Before the House Subcommittee on Labor-HHS-Education Appropriations. National Institute on Drug Abuse; 2012. Fiscal Year 2013 Budget Request. Accessible at: <https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2012/03/fiscal-year-2013-budget-request>
- Watson AM, Prasad KM, Klei L, Wood JA, Yolken RH, Gur RC, Bradford LD, Calkins ME, Richard J, Edwards N, Savage RM, Allen TB, Kwentus J, McEvoy JP, Santos AB, Wiener HW, Go RC, Perry RT, Nasrallah HA, Gur RE, Devlin B, Nimgaonkar VL. Persistent infection with neurotropic herpes viruses and cognitive impairment. *Psychological Medicine*. 2013; 43:1023–1031. DOI: 10.1017/S003329171200195X [PubMed: 22975221]
- Wechsler, D. Wechsler Intelligence Scale for Children - Third Edition: Manual. The Psychological Corporation; 1991.
- Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. *Schizophrenia Research*. 2011; 128:61–65. DOI: 10.1016/j.schres.2011.01.020 [PubMed: 21353483]

Figure 1.

Path model relating seropositivity for infections (HSV-1, EBV, CMV, or *T. gondii*) childhood intelligence (IQ), and risk for SUD in adulthood, controlling for socioeconomic status (SES), ethnicity (blacks or whites), and age at last available assessment. Error terms are not shown. SES is household SES (Hollingshead, 1975); parental SUD is indicated by the number of affected parents, sum of parental affectedness statuses (0, 1, or 2); IQ is Wechsler WISC-III full scale IQ

Table 1

Seropositivity in the sample

Sample	N	HSV (n=547)	EBV (n=537)	CMV (n=534)	T. gondii (n=510)
Total	569	98 (17.9%)	247 (46.0%)	244 (45.7%)	33 (6.5%)
Females	174	33 (19.6%)	82 (49.1%)	63 (40.1%)	9 (6.0%)
Males	395	65 (17.2%)	165 (44.6%)	181 (48.0%)	24 (6.7%)
F vs. M: χ^2 (p)		0.492 (.48)	0.941 (.33)	2.776 (.10)	0.078 (.78)

Table 2

Correlations between the predictors and the outcomes

Predictors	Outcomes			
	Males		Females	
	IQ	SUD	IQ	SUD
HSV	−0.18 (<.001)	0.06 (.225)	−0.15 (.049)	0.12 (.130)
EBV	−0.16 (.001)	0.10 (.062)	−0.31 (<.001)	0.21 (.006)
CMV	−0.06 (.259)	−0.08 (.130)	−0.10 (.206)	0.14 (.079)
<i>T. gondii</i>	−0.02 (.717)	0.07 (.209)	−0.04 (.638)	0.13 (.108)
IQ		−0.07 (.089)		−0.14 (.031)

Notes: The cells contain correlation coefficients (contingency coefficient between binary variables, point-biserial between binary and continuous variables, and product-moment between continuous variables), with their 2-tailed *p* values in parentheses. HSV, herpes simplex virus type 1; EBV, Epstein-Barr virus; CMV, cytomegalovirus; IQ, WISC-III full-scale IQ; SUD, DSM-III-R diagnosis of substance use disorder; SES, socioeconomic status.)

Table 3

Survival (Cox proportional hazard regression) analysis of the relationships between infections (each analyzed separately) and the rate of SUD development (household SES was entered as a covariate in all equations, and the analysis was stratified by ethnicity)

Predictor	Sex	Hazard ratio	95% CI	p
HSV-1	Males	1.3	0.91 – 1.99	.141
	Females	1.7	0.91 – 3.01	.097
CMV	Males	0.9	0.63 – 1.18	.359
	Females	1.7	1.01 – 3.04	.047
EBV	Males	1.3	0.95 – 1.80	.096
	Females	2.0	1.13 – 3.50	.016
T. gondii	Males	1.4	0.78 – 2.42	.278
	Females	1.9	0.74 – 4.74	.188

Table 4

Direct relationships in the path models (see Fig. 1)

Predictors	Dependent variables									
	males					females				
	IQ		SUD			IQ		SUD		
	b (95% CI)	P(b < 0)	b (95% CI)	P(b > or < 0)	b (95% CI)	P(b < 0)	b (95% CI)	P(b > or < 0)	P(b > or < 0)	
HSV	-3.4 (-6.55, 0.03)	0.97	0.03 (-0.16, 0.21)	0.61	-1.2 (-5.57, 3.13)	0.72	0.10 (-0.20, 0.39)	0.75		
EBV	-1.7 (-4.41, 1.01)	0.89	0.06 (-0.11, 0.22)	0.75	-1.2 (-5.11, 2.65)	0.73	0.15 (-0.13, 0.43)	0.85		
CMV	-0.9 (-3.60, 1.84)	0.74	-0.01 (-0.17, 0.16)	0.46	2.7 (-1.03, 6.56)	0.07	0.10 (-0.16, 0.36)	0.77		
<i>T. gondii</i>	-3.1 (-7.72, 1.46)	0.91	0.02 (-0.23, 0.25)	0.55	-1.6 (-8.00, 5.03)	0.70	0.01 (-0.35, 0.37)	0.53		
IQ			-0.002 (-0.008, 0.005)	0.70			-0.001 (-0.012, 0.011)	0.55		

Notes: the cells contain unstandardized estimates of path coefficients (*b*), with 95% credible intervals in parentheses that *b* is either less (for effects on IQ) or greater (for SUD) than 0. A 95% credible interval, CI (the Bayesian analog of confidence interval, approximately equal to it if the distribution is symmetric), is the range in which the true value of a parameter is located with 95% certainty. The P(*b*) values indicate the probability that the regression coefficient is either less than 0 (for the agent-IQ relationships and the IQ-SUD relationship) or greater than 0 (for the predictor-SUD relationships).